We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals

127 hedge funds and large institutions have $312M invested in Enanta Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 43 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

98% more capital inflows, than outflows

Capital inflows: $78M | Capital outflows: $39.4M

79% more call options, than puts

Call options by funds: $402K | Put options by funds: $225K

69% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 13

4% more funds holding

Funds holding: 122 → 127 (+5)

12% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 43

12.52% less ownership

Funds ownership: 93.73% → 81.21% (-13%)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
127
Holders Change
+5
Holders Change %
+4.1%
% of All Funds
1.57%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
22
Increased
38
Reduced
43
Closed
13
Calls
$402K
Puts
$225K
Net Calls
+$177K
Net Calls Change
-$137K

ENTA Hedge Fund Activity: Q3 2026 in Review

127 of the 8,114 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2026, worth a combined $312M — down 22% from $397M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ENTA positions and 13 closed out — a net gain of 9 holders — while 38 added to existing stakes and 43 trimmed.

The largest buyer was BlackRock, adding an estimated $8.48M. The largest seller was Farallon Capital Management, cutting an estimated $19.5M.

  • 127 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2026, up from 122 in Q2 2026.
  • Funds reported $312M of Enanta Pharmaceuticals stock for Q3 2026, down 22% quarter-over-quarter.
  • 22 funds opened new Enanta Pharmaceuticals positions in Q3 2026 and 13 closed out, a net change of +9 holders.
  • The largest Enanta Pharmaceuticals buyer in Q3 2026 was BlackRock, an estimated $8.48M added.
  • The largest Enanta Pharmaceuticals seller in Q3 2026 was Farallon Capital Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q3 2026.